Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
LBX Pharmacy Chain JSCSHSE:603883 +2.22%84 EV-to-EBITDA is 4.53 as of Sep. 21, 2026, which is 78% below its 10-year median of 20.23. GuruFocus rates SHSE:603883 with a GF Score™ of 84/100 and a GF Value™ of ¥18.15 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 523 Healthcare Providers & Services companies, LBX Pharmacy Chain JSC ranks better than 87.38% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, LBX Pharmacy Chain JSC's enterprise value is ¥11,941 Mil.
LBX Pharmacy Chain JSC's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was ¥2,635 Mil. Therefore, LBX Pharmacy Chain JSC's EV-to-EBITDA for today is 4.53.
The historical rank and industry rank for LBX Pharmacy Chain JSC's EV-to-EBITDA or its related term are showing as below:
SHSE:603883'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.44 Med: 20.23 Max: 41.57
Current: 4.53
During the past 13 years, the highest EV-to-EBITDA of LBX Pharmacy Chain JSC was 41.57. The lowest was 4.44. And the median was 20.23.
SHSE:603883's EV-to-EBITDA is ranked better than 87.38% of 523
companies
in the Healthcare Providers & Services industry
Industry Median: 10.08
vs SHSE:603883: 4.53
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
LBX Pharmacy Chain JSC's PE Ratio (TTM) for today is calculated as:
LBX Pharmacy Chain JSC's share price for today is ¥12.88.
LBX Pharmacy Chain JSC's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0.568.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, LBX Pharmacy Chain JSC's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
LBX Pharmacy Chain JSC EV-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, LBX Pharmacy Chain JSC's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where LBX Pharmacy Chain JSC's EV-to-EBITDA falls into.
LBX Pharmacy Chain JSC's current Enterprise Value is ¥11,941 Mil.
LBX Pharmacy Chain JSC's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥2,635 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LBX Pharmacy Chain JSC (SHSE:603883) has a EV-to-EBITDA of 4.53 as of Sep. 21, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on LBX Pharmacy Chain JSC. This is 78% below median its historical median of 20.23. Over the past decade, LBX Pharmacy Chain JSC's EV-to-EBITDA has ranged from 4.44 to 41.57. According to the industry distribution chart, LBX Pharmacy Chain JSC ranks #66 out of 523 companies in the Healthcare Providers & Services industry, placing it in the top 12.6%.
Is LBX Pharmacy Chain JSC's EV-to-EBITDA too high?
LBX Pharmacy Chain JSC's current EV-to-EBITDA of 4.53 is 78% below median its 10-year median of 20.23. Over the past 10 years, this metric has ranged from a low of 4.44 to a high of 41.57. The Healthcare Providers & Services industry median EV-to-EBITDA is 10.08. LBX Pharmacy Chain JSC's value of 4.53 is 55.1% below this industry median. Based on the distribution chart, LBX Pharmacy Chain JSC ranks #66 out of 523 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, LBX Pharmacy Chain JSC has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does LBX Pharmacy Chain JSC's EV-to-EBITDA compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, LBX Pharmacy Chain JSC ranks #66 out of 523 companies for EV-to-EBITDA. This places LBX Pharmacy Chain JSC in the top 13% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 10.08. LBX Pharmacy Chain JSC's value of 4.53 is 55.1% below this benchmark. Historically, LBX Pharmacy Chain JSC's own EV-to-EBITDA has ranged from 4.44 to 41.57 over the past decade. While the company's 10-year median is 20.23 vs. the industry median of 10.08, LBX Pharmacy Chain JSC has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Healthcare Providers & Services company?
The median EV-to-EBITDA among Healthcare Providers & Services companies is 10.08, based on 523 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. LBX Pharmacy Chain JSC's current EV-to-EBITDA of 4.53 is 55.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on LBX Pharmacy Chain JSC. For the Healthcare Providers & Services industry, the median EV-to-EBITDA is 10.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. LBX Pharmacy Chain JSC's current EV-to-EBITDA is 4.53, which is 78% below median its own 10-year median of 20.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LBX Pharmacy Chain JSC stock overvalued right now?
Based on GuruFocus' analysis, LBX Pharmacy Chain JSC (SHSE:603883) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥18.15, compared to a current price of ¥12.88 — trading 29% below its estimated fair value. The current EV-to-EBITDA is 4.53, which is 78% below median its 10-year median of 20.23 and 55.1% below the Healthcare Providers & Services industry median of 10.08. LBX Pharmacy Chain JSC's overall GF Score™ is 84/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For LBX Pharmacy Chain JSC (SHSE:603883), the current EV-to-EBITDA is 4.53 as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is LBX Pharmacy Chain JSC (SHSE:603883) Overvalued in 2026?
Based on GuruFocus' analysis, LBX Pharmacy Chain JSC stock appears to be undervalued.
The current stock price of ¥12.88 is trading 29% below its estimated GF Value™ of ¥18.15.
GuruFocus considers LBX Pharmacy Chain JSC to be Modestly Undervalued.
Key valuation signals for SHSE:603883:
EV-to-EBITDA: 4.53 (78% below median its 10-year median of 20.23)
GF Value™: ¥18.15 vs. price of ¥12.88 (29% below fair value)
Industry Position: 55.1% below the Healthcare Providers & Services median (#66 of 523)
No single metric tells the full story. See the SHSE:603883 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
LBX Pharmacy Chain JSC is a China-based company engages in the sale of medicine and health products. The company is engaged in retailing drugs and other related products, including Chinese and Western medicine, prepared slices of Chinese crude drugs, health equipment, healthy food, and personal care products and life care products. The company is also involved in the wholesale and manufacture of drugs.
84GF Score
Get the complete analysis for SHSE:603883
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603883 has been successfully added to your 
